Compare Amgen, Inc. (AMGN) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Rigetti Computing Inc — how do they compare? Amgen, Inc. trades at $393 (market cap $212.56B), while Rigetti Computing Inc trades at $15.26 (market cap $5.28B). The key difference: Amgen, Inc. is far larger — about 40.3× Rigetti Computing Inc's market cap, and Amgen, Inc. pays a 2.56% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals.
| AMGN | RGTI | |
|---|---|---|
Market Cap | $212.56B | $5.28B |
Sector | Health | Technology |
52-Week High | $444.12 | $56.34 |
52-Week Low | $271.18 | $12.90 |
Enterprise Value | $255.88B | $4.89B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN shares declined 10.08% to $393.17 following negative clinical trial news from competitor Novartis, creating technical bearish signals despite strong fundamental performance. The company maintains robust profitability with 22.95% net margins and has beaten earnings estimates for three consecutive quarters. Revenue growth continues with 2025 reaching $36.75 billion, though the stock faces near-term pressure from sector-specific concerns.
Long-term fundamentals remain strong with analyst consensus pointing to upside potential (target $398.52), but recent clinical setbacks in the cholesterol drug class create sector-wide uncertainty. The combination of attractive valuation metrics and consistent earnings beats supports investment appeal, though regulatory and competitive risks require monitoring.
Rigetti Computing (RGTI) trades at $15.81, up 4.01% today, amid mixed signals with bearish technical indicators but strong analyst support. The stock shows significant fundamental challenges with a P/S ratio of 391.11 and deeply negative profit margins (-1,787.4% net income margin), though recent government funding of $100 million provides crucial support. Technical analysis indicates bearish momentum with support at $15 and resistance at $17.
The outlook remains speculative with substantial execution risks and widening losses, offset by government backing and quantum computing potential. Investment opportunity hinges on long-term technology commercialization, while immediate risks include persistent cash burn and competitive pressures in the nascent quantum sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
